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Significance of this study
What is already known about this subject?
 ► Fatty acid (FA) profiles have been associated with 
gestational diabetes; however, most studies were 
performed during or after gestational diabetes mel-
litus (GDM) diagnoses and few have additionally in-
vestigated dietary intake.
What are the new findings?
 ► Plasma FA profiles in early pregnancy were different 
for women with and without GDM diagnoses later in 
pregnancy.
 ► Differences in plasma FA profiles were independent 
of the women’s body mass index.
 ► Women that were later diagnosed with GDM ap-
peared to have lower overall diet quality in early 
pregnancy.
How might these results change the focus of 
research or clinical practice?
 ► Further research is needed on early pregnancy FA 
profiles as a predicter for GDM.
 ► Increased dietary quality during pregnancy should 
be a clinical focus in GDM prevention.
AbStrAct
Introduction Fatty acid (FA) concentrations have 
previously been associated with gestational diabetes 
mellitus (GDM). However, few studies on GDM have 
examined FA profiles in early pregnancy or before 
diagnosis. This study aimed to compare early pregnancy 
plasma FA profiles of women with and without GDM 
diagnoses as well as their reported dietary consumption.
Research design and methods The subjects comprised 
853 women from the prospective study: Pregnant Women 
in Iceland II (PREWICE II), attending their 11–14 weeks 
ultrasound appointment in 2017–2018. During the visit, 
blood samples were collected for plasma FA analysis, and 
dietary habits were assessed using a short food frequency 
questionnaire. Information on GDM diagnoses was then 
later extracted from medical records. Differences in FA 
profile between GDM cases and non- cases were evaluated 
using the Mann- Whitney U test.
Results GDM was diagnosed in 127 women (14.9%). 
Concentrations of saturated fatty acids, monounsaturated 
fatty acids, polyunsaturated fatty acids (PUFA) n-6, 
PUFA n-3 and total FA were higher in the women who 
later developed GDM compared with those who did not 
(p≤0.05). The medians for total FA were 2898 μg/mL for 
the women with GDM and 2681 μg/mL for those without 
GDM. Mean adjusted difference for total FA between the 
groups was 133 μg/mL (95% CI 33 to 233). Similar results 
were observed in prepregnancy normal- weight women 
and overweight women/women with obesity. Overall diet 
quality in early pregnancy appeared to be lower among the 
women later diagnosed with GDM.
Conclusion We found that plasma FA profiles in early 
pregnancy were different for women later diagnosed with 
GDM compared with those who were not, independent of 
the women’s body mass index.
InTRoduCTIon
Gestational diabetes mellitus (GDM) is one 
of the most common pregnancy complica-
tions and a strong risk factor for later devel-
opment of type 2 diabetes (T2D).1 Potential 
risk factors for GDM include prepregnancy 
overweight and obesity, age and unhealthy 
dietary habits.2 With respect to dietary fat 
intake, high maternal intake of total fat,3 satu-
rated fatty acids (SFA) as well as cholesterol4 
have previously been associated with an 
increased risk of GDM,3 5 whereas intake of 
polyunsaturated fatty acid (PUFA) and alpha- 
linolenic acid (ALA) has been associated 
with reduced risk.6 Circulating FA can derive 
from both dietary intake7 and catabolism or 
endogenous synthesis, both of which being 
partly influenced by glucose homeostasis.8 
As an example, free fatty acid (FFA) levels 
have been associated with altered secretion 
of insulin as well as insulin resistance (IR), 
which may progress to diabetes.9–12
In most previous studies on FA profiles in 
pregnant cohorts, FA analysis was performed 
during or after GDM diagnoses,12 whereas 
few studies have investigated the FA profile 
during the first trimester, before GDM diag-
noses.13–17 Their results indicated that women 
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Figure 1 Participant flow chart. GDM, gestational diabetes 
mellitus; PREWICE II, Pregnant Women in Iceland II.
diagnosed later with GDM had higher total concentra-
tions of SFA,13–15 MUFA,13 15 PUFA n-616 and PUFA n-313 
and sometimes lower concentrations of PUFA n-613 15 and 
PUFA n-3.15–17
Our aim was to investigate whether the total plasma 
FA profile during the first trimester was associated with 
increased odds of GDM diagnoses. Because overweight 
and obesity can increase the risk of IR and GDM and is 
associated with altered FA profiles,12 we also stratified 
our analysis according to pre- pregnancy body mass index 
(BMI). Furthermore, self- reported dietary consumption 
was also compared between the two groups of women.
SubjeCTS and meTHodS
Subjects
Between October 2017 and March 2018, all pregnant 
women attending routine screening at gestational weeks 
11–14 at the Prenatal Diagnostic Unit at The National 
University Hospital (Reykjavik, Iceland) were invited to 
become participants in the study. Of the 1684 women 
scheduled for an appointment, 1350 were eligible by 
being able to answer an Icelandic Food Frequency Ques-
tionnaire (FFQ) in addition to their gestational age 
being between 11 and 14 weeks. Participant flow chart 
is shown in figure 1. A total of 1015 women agreed to 
participate (75%). Most of the women provided a blood 
sample during this routine visit, at which time additional 
tubes were drawn for the purpose of FA analysis. A total 
of 954 participants provided a non- fasting blood sample. 
We were able to acquire information on GDM diagnoses 
from medical data for 853 of these women; hence, the 
entire analysis consisted of 853 women or 84% of the 
enrolled study participants. The source population and 
cohort has been described in detail in previous publica-
tions.18 19
dietary intake and characteristics
During recruitment, the participants answered a short 
FFQ in electronic format on dietary intake, which also 
contained questions on age, education, smoking, parity, 
prepregnancy weight and height. The FFQ assessed the 
frequency of consumption of 40 food items and beverages 
and dietary supplement intake, requiring participants to 
refer to their intake during the previous 3 months. The 
women chose between 10 potential frequency responses 
ranging from ‘less than once a month’ to ‘more than 5 
times a day’. The FFQ development has previously been 
described in detail.18 20–22
In brief, the FFQ was pilot- tested and compared with 
results from a 4- day weighed food record with accept-
able correlation for most food groups/items (Spear-
man’s correlation >0.3).20 Recent publications from our 
PREWICE II study have described a dose- dependent 
association between the consumption of dairy and 
urine iodine concentration,18 wholegrain consumption 
and alkylresorcinol concentrations (a biomarker for 
wholegrains)19 and reported intake of vitamin D supple-
ments and 25- OH- D in plasma.22
measurement of plasma fatty acids in plasma
The voluntary blood samples provided at Landspi-
tali University Hospital in weeks 11–14 by consenting 
participants were processed within 1 hour after collec-
tion to separate plasma from red blood cells and buffy 
coat via centrifugation at 3000 rpm for 10 min. Plasma 
was aliquoted into cryotubes and stored in a freezer at 
−80°C until shipped for FA analysis at the Department of 
Biology and Biological Engineering, Chalmers University 
of Technology, Gothenburg, Sweden. The total plasma 
fatty acid (FA) composition was determined according to 
the method described by Stråvik et al,23 which is a modi-
fication of the method described by Masood et al.24 In 
total, 24 FA were quantified. An internal standard solu-
tion (100 µL of 0.1 mg C23:0 methyl ester/mL toluene) 
was added to 50 µL of thawed plasma samples, and 1.8 
mL of acetyl chloride- MeOH solution (10% (v/v) forti-
fied with butylated hydroxytoluene (2.78 µg/mL) was 
added. Samples were incubated at 70°C for 60 min in a 
water bath with shaking. Single extraction of fatty acid 
methyl esters (FAMEs) was carried out by adding 1.5 mL 
of hexane. The extraction solvent was evaporated using 
a vacuum concentrator (125 mbar, 30°C, 30 min). FAME 
was dissolved in 200 µL of hexane before injection into 
the GC- FID for analysis. Two water blanks (Millipore- 
purified water) and six quality controls (pooled plasma) 
were prepared and run together with the study samples 
for each batch of a maximum of 50 study samples.
FAMEs were separated using the GC- FID system 
(Thermo Scientific Focus GC, FID detector, Pal GC- xt 
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autosampler, AD-100 H2 generator and a MicroClip XT 
hydrogen gas alert and a ZA 1500 zero air generator) 
equipped with a Zebron ZB- FAME column (20 m×0.18 
µm ID×0.15 µm). The oven program was as follows: initial 
80°C with a 1.5 min hold; ramp: 40°C/min to 160°C, 
5°C/min to 185°C with a 0 min hold and then 30°C/min 
to 260°C with a 0 min hold. The instrumental condition 
was as follows: nitrogen as the carrier gas, constant flow, 
carrier flow 1.25 mL/min, Inlet temperature 260°C, split 
flow 12.5 mL/min, split ratio: 15. Detector temperature 
260°C. Gas flow: air 450 mL/min; hydrogen 35 mL/
min; makeup gas 10 mL/min. The injection volume was 
1 µL. The concentration of FAs in samples was quanti-
fied against external standard calibrations made from 
GLC-462 mixed FAMEs (Nu- Check Prep, Elysian, Minne-
sota, USA) dissolved in toluene. The external standard 
included 24 FAMEs ranging from C12:0 to C24:1. An 
equal amount of internal standard (C23:0 methyl ester) 
was added to the external standards as added to the study 
samples, and all analyte peaks were normalized with the 
peak of the internal standard before calibration.
Gestational diabetes mellitus diagnoses
The GDM diagnoses are based on The International 
Association of the Diabetes and Pregnancy Study Groups 
(IADPSG).25 During the first routine maternal care visit 
in Iceland (around 10 weeks of pregnancy), women at 
risk of developing GDM, based on age (≥40 years), BMI 
(≥30 kg/m2), ethnicity and history of diabetes or macro-
somia (≥4500 g), are invited to provide a fasting blood 
sample to measure fasting blood glucose. If results are 
≥5.1 mmol/L, the women are diagnosed with GDM or in 
some cases T2D, if fasting blood sugar is >7 mmol/L or 
hemoglobin A1c is ≥48 mmol/mol. The rate of women 
diagnosed with GDM during this early selective screening 
is unknown in Iceland. However, a study in France also 
using selective screening and the IADPSG criteria 
reported an early hyperglycemia rate of 2.3% in a cohort 
of almost 800 000 women, corresponding to 26.9% of the 
women diagnosed with hyperglycemia overall.26
Later in pregnancy, usually at weeks 24–28, the women 
considered at risk of GDM undergo a 2- hour oral glucose 
tolerance test (OGTT). During the OGTT blood sugar 
levels are measured during fasting, after 1 hour and 
after the second hour.27 Previously reported rates of 
GDM diagnoses in Iceland have been in the range of 
11.8%–16%.28 29 Information on GDM diagnoses for this 
study was gathered from medical records at the National 
University Hospital. The records did not always differen-
tiate between early detected GDM, GDMA1 (controlled 
with diet) or GDMA2 (medication needed); therefore, 
the GDM diagnoses cover all categories.
Statistical analysis
Data are presented as means and SD for normally distrib-
uted variables or median and 10th–90th percentiles for 
skewed distributions. A t- test for equality of means was 
used to compare the normally distributed variables, and 
Pearson’s χ2 test was used to compare dichotomous vari-
ables. The Mann- Whitney U test for two independent 
samples was used to compare differences for skewed 
variables.
For classification of FA groups, the concentrations of 
different types of FA were combined to determine the 
total for SFA, MUFA, PUFA n-6, PUFA n-3 as well as 
eicosapentaenoic acid (EPA) and docosahexaenoic acid 
(DHA) especially. Ratios of individual and groups of FA 
were calculated by dividing their concentration by the 
total FA concentration.
The value for six of the FA was below the limit of quan-
tification in a few cases. For four of the FA 0.1%–0.2% of 
the participants had levels below quantification, but for 
myristoleate (14:1) the rate was 3% and for docosatetrae-
noic (22:4) it was 10%. Values below limit of quantifica-
tion were set to half of the lowest value quantified for an 
FA in our data.
A linear regression model to compare means was used 
to evaluate the adjusted difference in FA types, between 
the women who were diagnosed later with GDM and 
those who were not.
Multivariate binary logistic regression was used to eval-
uate the OR of GDM across quartiles of FA types as well as 
relative FA. P for trend was evaluated by using the median 
value in each quartile and modeling the plasma FA and 
relative FA variables as continuous in the regression 
model. Results from the regression model are presented 
as multivariate- adjusted. A Spearman’s correlation was 
used to investigate correlations between dietary intake 
and FA. IBM Statistical Package for Social Sciences for 
Windows, V.24.0 (Armonk, New York, USA), was used to 
analyze the data. The level of significance was accepted 
as p<0.05.
Covariates
The covariates included in the adjusted models were 
selected a priori based on their potential influence on 
GDM diagnoses.30–34 In the adjusted linear regression 
model, covariates were age, prepregnancy BMI (kg/m2), 
weekly weight gain (kg/week) and maternal smoking 
during pregnancy.
The covariates included in our multivariate adjusted 
models were age; prepregnancy BMI (kg/m2); weekly 
weight gain (kg/week); parity (0, 1 and ≥2); maternal 
smoking during pregnancy (yes/no) and family history 
of diabetes (yes/no/unknown). In cases when missing 
values for covariates were low (<5%), they were imputed 
using the median or the most probable value, which was 
the case for prepregnancy BMI. When prepregnancy BMI 
values were missing (2.6% overall, 7.6% of the women 
diagnosed with GDM), values were imputed using the 
median or the most probable value based on BMI at the 
first maternal care visit. For family history of diabetes 
(missing=15%), missing values were accounted for by use 
of the missing category for covariate adjustment.
Medical records provided information on gestational 
age and maternal weight at maternal care visits. From 
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Table 1 Characteristics of the women in PREWICE II
All Non- GDM GDM
P value*(n=853) (n=726) (n=127)
Age, years 30.3±4.9 29.9±4.8 32.4±5.5 <0.01
Prepregnancy BMI†, kg/m2 25.8±5.7 25.4±5.4 28.4±6.8 <0.01
BMI ≥25 kg/m*, % 47 45 60
Total weight gain‡, kg 12.3±5.5 12.8±5.2 9.6±6.1 <0.01
Weight gain, kg/week§ 0.49±0.2 0.50±0.2 0.39±0.2 <0.01
Parity¶, %
  0 44 45 41
  1 36 35 40
  ≥2 20 20 19 0.60
Education**, %
  Elementary school 11 11 13
  Technical/High school 30 29 31
  University education 35 36 28
  Higher academic 24 24 28 0.36
Marital status††, %
  Married 24 23 26
  Living together 71 72 69
  Single 5 5 5 0.77
Smoking‡‡, %
  Before pregnancy: yes 14 14 17 0.39
  During pregnancy: yes 5 4 6 0.55
Family history of diabetes§§, % 7 6 14 <0.01
Data are presented as means±SD or ratios.
*Differences between non- GDM and GDM using t- test for equality of means, Pearson’s χ2 test and Mann- Whitney U test for two independent 
samples. Bold text indicates a statistically significant difference with a p- value ≤ 0.05.
†Information on prepregnancy BMI is missing for 22 women.
‡Information on weight gain is missing for 45 women. Total weight gain is the difference between measured weight at first and last maternal 
care visit.
§Weekly weight gain is the total weight gain divided by number of weeks between first and last maternal care visit.
¶Information on parity is missing for 6 women.
**Information on education is missing for 5 women.
††Information on marital status is missing for 21 women.
‡‡Information on smoking is missing for 6 women.
§§Information on family history of diabetes is missing for 128 women.
BMI, body mass index; GDM, gestational diabetes mellitus; PREWICEII, Pregnant women in Iceland II.
these data, we were able to calculate total weight gain and 
weight gain per week by dividing total weight gain with 
the number of weeks between visits.
Self- reported prepregnancy weight and height from 
the FFQs was used to calculate prepregnancy BMI (kg/
m2). A BMI <18.5 kg/m2 was defined as underweight, 
18.5–24.9 kg/m2 as normal weight, 25–29.9 kg/m2 as 
overweight and ≥30.0 kg/m2 as obese.
ReSulTS
Characteristics of the participants are presented in 
table 1.
The mean age of all participants was 30 years, and 
44% were nullipara. In total, 59% had a university- level 
or higher academic education, and 14% smoked before 
pregnancy. The prevalence of GDM diagnoses was 14.9% 
(n=127). The women diagnosed with GDM were more 
likely to be older and have a higher prepregnancy BMI. 
They were, therefore, also more likely to be overweight or 
obese prior to pregnancy (59.8%) compared with women 
without GDM (44.6%).
The concentrations of total and relative SFA, MUFA, 
PUFA n-6 and n-3 at gestational weeks 11–14 are provided 
in table 2, whereas the concentrations of individual FAs 
for women with and without later GDM diagnoses are 
presented in online supplemental table 1.
The total concentration of FA was significantly higher in 
women diagnosed with GDM, as were the concentrations 
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Table 2 Fatty acid concentrations at gestational weeks 11–14 in women with and without GDM diagnosis later in pregnancy, 







Median (10th–90th percentile) Median (10th–90th percentile)
Total μg/mL μg/mL (95% CI)† Ratio %‡
All (n=726) (n=127) (n=726) (n=127)
SFA 906 (712–1166) 966 (747–1230) <0.01 37 (1 to 75) 34 (32–36) 33 (31–36) 0.39
MUFA 688 (521–928) 784 (562–1041) <0.01 75 (40 to 110) 26 (23–29) 27 (24–31) <0.01
PUFA n-6 955 (793–1178) 989 (813–1188) 0.02 21 (−11 to 52) 36 (32–40) 35 (31–38) <0.01
PUFA n-3 128 (94–177) 134 (99–180) 0.05 −0,3 (−8 to 7) 4.7 (3.7–6.2) 4.6 (3.8–5.9) 0.38
EPA+DHA 93 (66–135) 97 (73–133) 0.11 −2 (−8 to 5) 3.4 (2.5–4.8) 3.4 (2.6–4.5) 0.40
Total fatty 
acids
2681 (2174–3392) 2898 (2287–3632) <0.01 133 (33 to 233) – –
BMI <25 kg/m2 (n=396) (n=44) (n=396) (n=44)
SFA 887 (705–1153) 941 (730–1282) 0.17 45 (−11 to 100) 34 (32–36) 34 (31–36) 0.54
MUFA 660 (516–906) 753 (522–1034) <0.01 88 (38 to 138) 25 (22–29) 27 (23–30) <0.01
PUFA n-6 947 (789–1178) 969 (769–1203) 0.18 24 (−23 to 72) 36 (32–40) 35 (32–38) 0.02
PUFA n-3 126 (93–178) 133 (99–176) 0.14 3 (−8 to 15) 4.7 (3.8–6.2) 4.7 (3.8–6.0) 0.99
EPA+DHA 92 (64–133) 98 (73–136) 0.14 2 (−7 to 12) 3.4 (2.5–4.8) 3.5 (2.6–5.0) 0.87
Total fatty 
acids
2615 (2127–3340) 2773 (2178–3701) 0.04 161 (14 to 307) – –
BMI >25 kg/m2 (n=324) (n=77) (n=324) (n=77)
SFA 918 (727–1186) 973 (766–1231) 0.01 30 (−23 to 83) 34 (31–36) 33 (31–36) 0.68
MUFA 717 (535–962) 822 (570–1092) <0.01 60 (12 to 109) 26 (23–30) 27 (24–32) <0.01
PUFA n-6 963 (796–1180) 990 (814–1191) 0.07 16 (−27 to 59) 36 (32–39) 35 (30–38) 0.01
PUFA n-3 131 (95–181) 134 (104–182) 0.34 −3 (−13 to 6) 4.7 (3.7–6.2) 4.6 (3.8–5.9) 0.30
EPA+DHA 96 (67–136) 95 (74–132) 0.52 −5 (−12 to 3) 3.5 (2.6–4.7) 3.3 (2.5–4.5) 0.27
Total fatty 
acids
2769 (2210–3412) 2944 (2323–3632) <0.01 103 (−35 to 240) – –
Bold text indicates a statistically significant difference with a p- value ≤ 0.05.
*BMI information is missing for 12 women.
†Adjusted for age, prepregnancy BMI, weekly weight gain and smoking during pregnancy when all women are included. No adjustment for prepregnancy BMI when 
stratifying for BMI.
‡Relative FA concentrations as a ratio of total FA.
BMI, body mass index; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; FA, fatty acids; GDM, gestational diabetes mellitus; MUFA, monounsaturated 
fatty acids; PUFA, polyunsaturated fatty acids; SFA, saturated fatty acids.
of all types of FA, except for long n-3 FAs EPA+DHA. 
When stratified by prepregnancy BMI (<25 kg/m2 vs 
≥25 kg/m2), the same tendency toward a higher concen-
tration of total FA and MUFA in women who later were 
diagnosed with GDM was observed in both groups. When 
comparing relative FA concentrations of women later 
diagnosed with GDM with those who were not, MUFA 
was significantly higher, and PUFA n-6 was significantly 
lower for the women who later developed GDM. This 
difference remained after stratifying by prepregnancy 
BMI (<25 kg/m2 vs ≥25 kg/m2).
Table 3 shows the OR for developing GDM according 
to quartiles of FA concentrations (total plasma concen-
tration and ratio of total plasma concentration).
When examining the total concentration, a significant 
trend toward increased odds of GDM was noted with 
higher concentrations of MUFA, PUFA n-6 and total FA. 
However, when FA was expressed as a ratio of total plasma 
concentration, increased odds for GDM were seen with a 
higher ratio of MUFA. The odds of GDM were lower in 
the highest quartile of PUFA n-6 ratio compared with the 
lowest quartile, although p for trend did not reach signif-
icance. No association was observed between PUFA n-3 
and GDM; neither for total concentration nor the ratio 
of total plasma PUFA n-3.
Table 4 shows a comparison of dietary intake in early 
pregnancy between the women who were later diagnosed 
with GDM and those who were not.
Women who were later diagnosed with GDM had a 
significantly lower intake of fatty fish and skimmed milk 
compared with women who did not develop GDM. They 
also tended to use a higher proportion of saturated fat 
but a lower proportion of vegetable oil when cooking 
(50% vs 29% p=0.06) versus (50% vs 71% p=0.06), 
respectively. Reported intake of omega-3 supplements 
also tended to be lower for women who were later diag-
nosed with GDM, with differences close to significance. 
Other differences observed in dietary intake between the 
two groups included a lower frequency intake of whole 
grains, fruit juice, beans, nuts, seeds and coffee during 
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Table 3 The associations between quartiles of fatty acid concentrations and ratios with GDM diagnoses
N=853
Total plasma* Ratio† of total plasma*
Median (μg/mL) No. cases (%)/n OR (95% CI) Median % No. cases (%)/n OR (95% CI)
SFA quartile
SFA- Q1 736 22 (10.3)/213 1.00 31.7 36 (16.8)/214 1.00
SFA- Q2 855 28 (13.1)/214 1.05 (0.55 to 1.99) 33.0 29 (13.5)/215 0.67 (0.37 to 1.22)
SFA- Q3 970 33 (15.5)/213 1.11 (0.58 to 2.13) 34.0 34 (16.1)/211 1.14 (0.64 to 2.03)
SFA- Q4 1145 44 (20.7)/213 1.69 (0.92 to 3.11) 35.8 28 (13.1)/213 0.76 (0.41 to 1.40)
P- trend 0.059 0.65
MUFA quartile
MUFA- Q1 541 21 (9.9)/213 1.00 23.1 16 (7.5)/213 1.00
MUFA- Q2 646 21 (9.8)/214 0.77 (0.39 to 1.53) 25.0 19 (8.9)/214 0.89 (0.42 to 1.87)
MUFA- Q3 750 29 (13.6)/213 0.87 (0.45 to 1.70) 26.6 37 (17.4)/213 1.82 (0.94 to 3.52)
MUFA- Q4 925 56 (26.3)/213 2.21 (1.22 to 3.99) 29.0 55 (25.8)/213 3.01 (1.16 to 5.67)
P- trend 0.001 <0.001
PUFA n-6 quartile
PUFA n-6- Q1 812 26 (12.2)/213 1.00 32.2 41 (19.2)/213 1.00
PUFA n-6- Q2 916 26 (12.1)/214 0.94 (0.49 to 1.81) 34.6 36 (16.7)/215 1.03 (0.58 to 1.81)
PUFA n-6- Q3 1009 28 (13.1)/213 1.02 (0.54 to 1.92) 36.5 34 (16.0)/212 1.08 (0.61 to 1.91)
PUFA n-6- Q4 1161 47 (22.1)/213 1.67 (0.94 to 2.99) 38.9 16 (7.5)/213 0.47 (0.24 to 0.94)
P- trend 0.046 0.065
PUFA n-3 quartile
PUFA n-3- Q1 97 22 (10.3)/213 1.00 3.8 31 (14.6)/213 1.00
PUFA n-3- Q2 120 34 (16.0)/213 1.62 (0.85 to 3.07) 4.4 37 (17.3)/214 1.13 (0.63 to 2.02)
PUFA n-3- Q3 140 35 (16.4)/214 1.22 (0.64 to 2.34) 5.0 33 (15.5)/213 0.97 (0.53 to 1.79)
PUFA n-3- Q4 173 36 (16.9)/213 1.37 (0.72 to 2.59) 5.9 26 (12.2)/213 0.67 (0.35 to 1.25)
P- trend 0.59 0.14
Total plasma 
concentration
Total FA- Q1 2237 23 (10.8)/213 1.00 – – –
Total FA- Q2 2570 22 (10.3)/214 0.74 (0.38 to 1.47) – – –
Total FA- Q3 2886 32 (15.0)/213 1.10 (0.59 to 2.07) – – –
Total FA- Q4 3323 50 (23.5)/213 1.76 (0.98 to 3.16) – – –
P- trend 0.014
Bold text indicates a statistically significant difference with a p- value ≤ 0.05.
*Adjusted for age, prepregnancy BMI, parity, weekly weight gain, smoking during pregnancy, family history of diabetes.
†Relative FA concentrations as a ratio of total FA.
BMI, body mass index; FA, fatty acids; GDM, gestational diabetes mellitus; MUFA, monounsaturated fatty acids; PUFA, polyunsaturated fatty acids; 
SFA, saturated fatty acids.
early pregnancy in women who later were diagnosed with 
GDM.
There were no clear correlations between dietary 
intake and FA concentrations except in the case of fatty 
fish and omega-3 supplements, both of which correlated 
positively with concentrations of PUFA n-3 and EPA+DHA 
(online supplemental tables 2 and 3) pregnancy (59.8%) 
compared with women without GDM (44.6%).
One limitation of our study is that we did not have 
exact data at the time of diagnoses for our GDM cases. 
As subjects with known risk factors are more likely to be 
diagnosed early (online supplemental table 4), we exam-
ined the concentrations of total and relative SFA, MUFA, 
PUFA n-6 and n-3, excluding all women with known risk 
factors that prompt early GDM screening (BMI ≥30 kg/
m2, age ≥40 years and parity ≥1, to exclude all women 
with previous GDM/macrosomia).
dISCuSSIon
We found that the total concentrations of plasma FAs, as 
well as total MUFA and MUFA ratio measured at 11th–
14th week of pregnancy, were significantly higher and 
PUFA n-6 ratios lower in women who were later diag-
nosed with GDM, independent of the women’s BMI. The 
fact that stratifying by BMI did not alter our results is 
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Table 4 FFQ reported weekly intake of foods at 11th–14th week of pregnancy*
FFQ, frequency per week†
Non- GDM (n=742) GDM (n=123)
P value‡Median (10th–90th percentile)
Fish, fatty 0.5 (0.1–1.0) 0.1 (0.1–1.0) <0.01
Fish, lean 1.0 (0.1–2.5) 1.0 (0.1–2.5) 0.39
Omega-3 supplements 1.0 (0.3–14.1) 0.3 (0.3–10.9) 0.09
Red meat 1.0 (0.1–2.5) 1.0 (0.1–2.5) 0.94
Poultry 1.0 (0.1–2.5) 1.0 (0.1–2.5) 0.41
Processed meat 0.5 (0.1–2.5) 0.5 (0.1–1.3) 0.39
Whole milk 0.1 (0.1–5.0) 0.1 (0.1–7.0) 0.68
Low fat milk 1.0 (0.2–7.1) 0.6 (0.2–14.1) 0.55
Skimmed milk 0.2 (0.2–1.7) 0.2 (0.2–1.1) 0.02
Sour dairy 2.5 (0.1–7.0) 2.5 (0.1–7.0) 0.18
Cheese 5.0 (1.0–14.0) 5.0 (1.0–14.0) 0.11
Butter on bread 5.0 (0.5–14.0) 5.0 (0.3–7.0) 0.42
Butter for cooking 1.0 (0.1–5.0) 2.5 (0.1–5.4) 0.76
Vegetable oil for cooking 5.0 (1.0–7.0) 2.5 (0.3–7.0) 0.07
French fries and chips 0.5 (0.3–2.5) 0.5 (0.1–2.5) 0.53
Cakes, sweets, ice cream and cookies 3.5 (1.0–8.0) 3.0 (0.6–7.5) 0.11
Soft drinks 1.5 (0.2–7.1) 2.6 (0.2–10.8) 0.44
Fruit juice 1.0 (0.1–7.0) 0.5 (0.1–7.0) 0.01
Fruits and vegetables 14.0 (5.0–39.0) 14.0 (3.4–39.0) 0.12
Beans, nuts and seeds 0.5 (0.1–5.0) 0.5 (0.1–2.5) 0.01
Wholegrains 6.0 (1.2–15.0) 4.0 (0.5–19.2) <0.01
White bread 2.5 (0.1–7.0) 2.5 (0.1–7.0) 0.97
Coffee 0.5 (0.10–14.0) 0.1 (0.1–7.0) 0.01
*Data are presented as medians and percentiles (10th–90th).
†FFQ information on intake is missing for six participants.
‡Differences between non- GDM and GDM using the Mann- Whitney U test for two independent samples. Bold text indicates a statistically 
significant difference with a p- value ≤ 0.05.
FFQ, Food Frequency Questionnaire; GDM, gestational diabetes mellitus.
important to note because obesity, IR and FA profiles in 
GDM are strongly inter- related.12
In most previous studies on FA profiles in pregnancy 
cohorts, FA analysis was performed during or after GDM 
diagnoses.12 These studies found that SFA concentrations 
appeared to be higher in women diagnosed with GDM 
when compared with a control group and that PUFA n-6 
and PUFA n-3 concentrations were both lower in women 
with GDM.12 A recent meta- analysis similarly reported 
that women with GDM had higher total concentrations 
of FFAs in the second and third trimester compared with 
women without GDM, with concentrations decreasing as 
pregnancy progressed.35
The results of the few studies that have investigated FA 
concentrations in early pregnancy, prior to GDM diag-
nosis, agree with the present study’s findings, showing 
higher total concentrations of SFA13–15 and MUFA13 15 as 
well as PUFA n-616 and PUFA n-313 in women who were 
later diagnosed with GDM compared with those who were 
not. On the other hand, some of these studies reported 
lower PUFA n-613 15 and PUFA n-315–17 concentrations in 
women who later received a GDM diagnosis.
FA profiles have been proposed as a means of 
predicting later T2D diagnosis in non- pregnant popu-
lations, where higher relative concentrations of FFA,36 
PUFA n-6,37 MUFA36 37 and SFA36 37 have been associated 
with an increased risk of impaired glucose tolerance and 
T2D risk. These studies have reported similar results as 
observed for circulating FA in the pregnant population 
in our study. Associations between higher PUFA n-6 rela-
tive to total FA and increased insulin sensitivity have also 
been found in previous studies in non- pregnant popula-
tions,36 which is in accordance with the results seen in the 
present pregnancy cohort.
The FA profiles may be a result of differences in intake or 
absorption of both carbohydrates and fat.12 Plasma MUFA 
and SFA concentrations do not only represent dietary intake 
as FAs can be synthesized endogenously, mainly from carbo-
hydrates, which is then referred to as de novo lipogenesis.38 39 
Other factors that could influence FA profile are FA synthesis 
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and incorporation of FA into cell membranes. It remains 
unclear how the plasma total FA profile is physiologically 
associated with diabetes. Lipogenesis is stimulated by insulin 
and suppressed by the hormones glucagon and epineph-
rine. Some studies have suggested that higher FFA may alter 
insulin signalling, secretion and glucose production.40 41 It 
is, therefore, possible that an abnormal increase of insulin 
in the blood may lead to higher FA concentrations and vice 
versa.
Some differences were found in food consumption in 
the first trimester between women with and without GDM 
diagnoses, and it is not clear how this difference might 
be reflected in the plasma FA profile. It could have been 
expected to see a difference in EPA and DHA concentra-
tions between the two groups because women who later were 
diagnosed with GDM had a less frequent intake of both fatty 
fish and omega-3 supplements. However, because FA can be 
synthesized endogenously from excess carbohydrates, the 
overall quality of the diet, including carbohydrate quality 
and amount consumed, might explain some of the differ-
ence observed in FA concentration between the two groups, 
overall carbohydrate quality being one.19 21 42
As we have previously reported in this cohort, the women 
who were later diagnosed with GDM had lower quality of 
carbohydrate intake as they had a lower intake of wholegrains 
(estimated by biomarkers).19 Intake of soft drinks also tended 
to be greater for women diagnosed with GDM as well as use 
of saturated fat for cooking, even though the difference was 
not statistically significant. This could suggest that the overall 
diet quality in early pregnancy was lower among the women 
later diagnosed with GDM.
In summary, a stronger association has been observed 
between plasma FA and diabetes risk compared with 
dietary intake estimates.37 It is important to note that 
different sources of FA measurements can represent 
varying dietary intake periods, such as adipose tissue 
(long- term FA intake 1–1.5 years), skeletal muscle cells, 
erythrocytes (120 days), serum, total plasma, phospho-
lipids (1–2 weeks12), cholesteryl esters and FFAs.37 Eryth-
rocytes have been claimed as a preferable option to 
evaluate differences in recent FA intake, at least regarding 
PUFA n-3.39 However, FA from erythrocytes and plasma 
have been found to correlate.37 In our study, we analyzed 
total plasma FA, which includes the FAs from cholesteryl 
esters, phospholipids, triacyclglycerols and FFA thought 
to represent very recent intake (1–2 weeks), whereas the 
answers in the FFQ covered intake during the previous 3 
months.
It might be considered a limitation that our partic-
ipants were not fasting. This might have resulted in 
lower concentrations of FFA because they are reduced in 
response to higher insulin levels postmeals43 and makes 
a comparison with other studies challenging. However, 
comparisons of our results with other studies may be 
affected by the non- fasting state of our participants and 
by the difference in methodology used when analysing FA 
profiles. Another limitation is that we did not have exact 
information on date of diagnoses, thereby part of our 
GDM cases may have received their diagnosis at or close 
to drawing of the blood sample in which FA profiles were 
quantified. However, we did see a similar trend in the 
results (online supplemental 4) when we ran our analysis 
excluding all women with known risk factors that prompt 
early GDM screening (BMI, age and previous GDM/
macrosomia). We therefore believe that this limitation 
did not majorly affect our main results.
The strength of our study is that we analyzed plasma 
FA early in pregnancy, in addition to acquiring subjective 
data on dietary intake. Our study also features prospec-
tively collected data from a large sample size of 853 
pregnant women with high participation rate (75%). We 
report both total concentrations of all FA subgroups as 
well as their ratios. We adjusted for BMI, and stratified our 
FA results by BMI, a process that, to our knowledge, has 
not been previously performed in a pregnancy cohort.
In conclusion, we found that women who were later 
diagnosed with GDM had a higher concentration of total 
plasma FA, total MUFA and MUFA ratios as well as lower 
PUFA n-6 ratios in early pregnancy, independent of the 
women’s BMI, compared with women who remained free 
of GDM. The women who were not diagnosed with GDM 
also tended to have better diet quality in early pregnancy. 
These results suggest that FA biomarkers in early preg-
nancy may predict GDM. However, further studies are 
required to confirm this hypothesis.
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